RecruitingBiliary Atresia

A Prospective Database of Infants With Cholestasis

Eligible age

Up to 0.5 yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediatric liver diseases.

Sponsor: Arbor Research Collaborative for Health

You may qualify if…

✓ Infant's age less than or equal to 180 days at initial presentation at the ChiLDReN clinical site.
✓ Diagnosis of cholestasis defined by serum direct or conjugated bilirubin greater than or equal to 2 mg/dl and suspected biliary atresia.
✓ The subject's parent(s)/guardian(s) willing to provide informed written consent.

You may not qualify if…

✕ Acute liver failure.
✕ Previous hepatobiliary surgery with dissection or excision of biliary tissue.
✕ Diagnoses of bacterial or fungal sepsis (except where associated with metabolic liver disease)
✕ Diagnoses of hypoxia, shock or ischemic hepatopathy within the past two weeks (If the cholestasis persists beyond two weeks of the initiating event, the infant can be enrolled).
✕ Diagnosis of any malignancy.
✕ Presence of any primary hemolytic disease (except when diagnosed with biliary atresia or another cholestatic disease being studied by ChiLDREN).
✕ Diagnosis of any drug or Total parenteral nutrition (TPN)-associated cholestasis (except when diagnosed with biliary atresia or another cholestatic disease being studied by ChiLDREN).
✕ Diagnosis with Extracorporeal membrane oxygenation (ECMO)-associated cholestasis.